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Background: Stomach cancer is the third deadliest among all cancers worldwide. Although incidence of the
intestinal-type gastric cancer has decreased, the incidence of diffuse-type is still increasing and its progression is
notoriously aggressive. There is insufficient information on genome variations of diffuse-type gastric cancer because its
cells are usually mixed with normal cells, and this low cellularity has made it difficult to analyze the genome.
Results: We analyze whole genomes and corresponding exomes of diffuse-type gastric cancer, using matched tumor
and normal samples from 14 diffuse-type and five intestinal-type gastric cancer patients. Somatic variations found in
the diffuse-type gastric cancer are compared to those of the intestinal-type and to previously reported variants.
We determine the average exonic somatic mutation rate of the two types. We find associated candidate driver
genes, and identify seven novel somatic mutations in CDH1, which is a well-known gastric cancer-associated
gene. Three-dimensional structure analysis of the mutated E-cadherin protein suggests that these new somatic
mutations could cause significant functional perturbations of critical calcium-binding sites in the EC1-2 junction.
Chromosomal instability analysis shows that the MDM2 gene is amplified. After thorough structural analysis, a
novel fusion gene TSC2-RNF216 is identified, which may simultaneously disrupt tumor-suppressive pathways and
activate tumorigenesis.
Conclusions: We report the genomic profile of diffuse-type gastric cancers including new somatic variations, a
novel fusion gene, and amplification and deletion of certain chromosomal regions that contain oncogenes and
tumor suppressors.Background
Stomach cancer ranks as the third most important cause
of global cancer mortality [1]. Histopathologically, gastric
cancer (GC) can be classified into two categories based on
morphological differences: intestinal-type GC (IGC) and
diffuse-type GC (DGC) [2,3]. IGC is typically associated
with Helicobacter pylori infection, and is especially com-
mon in Japan and Korea [4-6]. DGC is uniformly distrib-
uted geographically, and includes aggressive clinical forms,* Correspondence: jongbhak@genomics.org; nslsh@ncc.re.kr
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unless otherwise stated.such as linitis plastica, which have poor prognosis, especially
in young patients [7,8]. Genomic DNA modifications leading
to GC can happen as a result of several environmental risk
factors such as a high-salt diet and tobacco smoking [9]. Al-
though the incidence of IGC has decreased steadily over sev-
eral decades (44% reduction from 1978 to 2005), DGC
increased rapidly (by 62%) from 1978 up to 2000, before de-
creasing slightly in 2001–2005 [10]. Despite the cumulative
evidence that IGC and DGC develop via different carcino-
genic pathways [11,12], detailed genomic scale data for DGC
are lacking because of limited availability of clinical samples
and a low level of purity of the cancer cell population.
To date, very few genes associated with GC subtypes
have been identified. The CDH1 gene, which encodes the
E-cadherin protein, are the best-known genes associated
with hereditary DGC (HDGC) [13-16]. Genetic screening. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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nose early-onset GC [17]. E-cadherin dysfunction, caused
by mutations, loss of heterozygosity, and promoter hyper-
methylation, is the most well-established defect in GC
initiation and development [18-20]. A genome-wide
association study showed that polymorphisms in the
prostate stem cell antigen gene (PSCA) are strongly asso-
ciated with susceptibility to DGC [21]. The microarray-
based method, however, is limited to single nucleotide
variations, and cannot detect copy-neutral structural
variations (SVs). Two recent studies reported on GC
exomes, and showed that mutations in the ARID1A
gene are frequently detected in GC with microsatellite
instability, and in Epstein-Barr virus (EBV)-positive
GCs [22,23]. No analysis of GC subtypes was per-
formed, and the majority of the samples analyzed in
the studies were from patients with IGC.
Next-generation sequencing (NGS) has allowed re-
searchers to detect disease-associated variations, and
helped uncover the underlying mechanisms of disease
development. In particular, whole genome sequencing
(WGS) can detect most genomic variations, including
SVs, such as intrachromosomal and interchromosomal
rearrangements. Alternatively, whole exome sequencing
(WES), a captured-target sequencing method, can be used
for high-depth sequencing of a large number of samples at
a relatively low cost [24], although only single nucleotide
variations (SNVs) and small insertions or deletions (indels)
can be identified using this method. WGS and WES each
have advantages and disadvantages, and a number of re-
cent studies have used both methods [25-27].
Here we present detailed characterization of DGC ge-
nomes from matched tumor and normal samples by
generating whole genomic profiles followed by WES.
We used blood samples as a normal control, as in pre-
vious studies [28-31]. In order to find DGC-specific
variations, IGC genomes were also analyzed and com-
pared with variations identified in genomes of DGCs.
Three-dimensional protein structure analysis was per-
formed for novel somatic mutations of the CDH1 gene,
and this identified critical regions that were functionally
altered by the mutations. In addition, we found a novel fu-
sion gene that could be involved in tumorigenesis.
Results and discussion
Whole genome and exome sequencing
Tumor and matched normal (blood) samples from 14 pa-
tients with DGC (the clinicopathological characteristics of
these patients are shown in Table S1 in Additional file 1),
who were all relatively young (median age 38 years)
Korean women, were sequenced using an Illumina HiSeq
2000, which produced paired-end, 90-base and 101-base
DNA reads. Additionally, five pairs of tumor and matched
normal samples from patients with IGC (median age42 years) were subjected to DNA sequencing; one of these
samples was identified later as a case of microsatellite in-
stability (MSI) and hence was excluded from the mutation
analysis. None of the samples had any familial history of
cancer, and the subtypes were histopathologically con-
firmed. Only tumor cells were collected by macrodissec-
tion after hematoxylin staining.
For the whole genome analysis, on average, 92 giga-
bases (Gb) per sample were produced at approximately
32 times sequencing depth, reaching 3.5 terabases (Tb)
in total, and were mapped to the reference genome
(NCBI build 37, hg19) at a mapping rate greater than
94.5% (for sequencing statistics, see Additional file 1:
Table S2). Using the final 3.3 Tb of mapped reads, a gen-
omic profile database was constructed for detecting
SNVs, copy number variations (CNVs), and SVs. Because
the cellular purity of a tumor sample is a critical feature
in cancer genome analysis, it was evaluated using an in-
house calculation method (see Materials and Methods;
see Additional file 1: Table S3 and Figure S1). Although
we tried to collect only tumor cells, our samples still
showed a high level of stromal admixture. To increase
the accuracy of mutation detection in genic regions even
in low-purity samples, additional WES was performed at
approximately 103 times sequencing depth on average,
which produced a total of 17 Gb sequence data. The
captured WES covered 93.1% of the genic region at 10
times or greater depth, and this coverage is similar to
that of previously reported exome data on GC [22,23].
Combining the WGS and WES data, we detected som-
atic alterations in the DGC samples, and compared them
with the IGC alterations (the data are summarized in
Figure 1 as a circus diagram). To verify our data, we
combined and analyzed them with previously reported
exome data from two different studies (24 IGC and 5
DGC samples, not including MSI and mixed samples)
[22,23] and from array comparative genome hybridization
(CGH) data (16 IGC and 14 DGC samples) [32]. Although
those studies used mainly IGCs and included only a small
number of DGC samples, they could be complementary
to our data as a control (by providing an increased num-
ber of IGC data and elimination of tissue specificity). In
the combined dataset, we compared the differences in al-
terations between the DGC and IGC samples.
Identification of diffuse-type-specific SNVs and indels
In each sample pair, we identified approximately 3.7 million
SNVs, which were verified using single nucleotide poly-
morphism (SNP) chips (average concordance rate: 99.2%;
see Additional file 1: Table S4), and approximately 0.69 mil-
lion indels (for details, see Additional file 1: Table S5 and
Table S6). We first assessed mutational frequency of both
types of GC at the single nucleotide level (see Additional
file 1: Figure S2 a, b). The somatic mutation spectrum was
Figure 1 Whole genome distribution of somatic mutations and duplication or deletion events in diffuse-type gastric cancers (DGCs). All the
somatic mutations, including duplication/deletion events, which were found in the 14 DGC genomes, are merged in the circus plot. From outside to
inside, the plot presents the following characteristics: chromosome ideograms, frequency of cumulative amplification or deletion events (black,
amplification; red, deletion), and the number of somatic non-synonymous single nucleotide variations (nsSNVs), indels, and SNVs in splice sites for each
gene. Black triangles indicate highly mutated genes. Orange triangles denote oncogenes, and blue triangles indicate the tumor suppressors.
Lee et al. Genome Biology 2014, 15:R55 Page 3 of 15
http://genomebiology.com/2014/15/4/R55dominated by C >T (G >A) transitions in both the DGC
and IGC samples, and there were no significant differences
in mutational contexts between the two GC types, in ac-
cordance with previous studies of GC [23,30]. When we
analyzed two previously reported exome datasets, we found
that the spectrum of the nucleotide substitution ratio was
similar to our data (see Additional file 1: Figure S2c, d).
Although the mutation spectrum of DGC is similar to
that of IGC, individual mutations in affected genes were
different. By subtracting mutations found in normal blood
genomes, we identified 922 non-synonymous SNVs
(nsSNVs) as somatic mutations in the 18 tumor sam-
ples (see Additional file 1: Table S7; see Additional file 2).
The average mutation rate of the 18 GCs (1.97 mutations/
Mb) was comparable with that reported in other studies
on colon, pancreatic, and liver cancers [33-35]. Of 847
mutated genes affected by the 922 nsSNVs, 581 were in 14
DGC cases, 288 were in 4 IGC cases, and 22 (2.6%) were
common to both types. The MSI sample, which wasexcluded from the comparative analysis, showed approxi-
mately six times more SNVs and indels than did the other
samples; this result is in agreement with a previous report
[22]. When we combined the two previously reported ex-
ome datasets, we identified 967 and 2,077 somatic nsSNVs
in 19 DGCs and 28 IGCs, respectively. The somatic muta-
tion rate of the IGCs (3.71 mutations/Mb in the 28 sam-
ples) was higher than that of the DGCs (2.29 mutations/
Mb in the 19 samples) (see Additional file 1: Table S8).
Previously published research suggests that melanoma
and lung cancer have high mutation rates, owing to the in-
volvement of potent mutagens [36]. Likewise, it is possible
that IGC has this high mutation rate because its tumori-
genic mechanism may be associated more with environ-
mental and/or parasitic mutagens compared with DGC.
For individual variations, putative cancer-causative
genes were predicted by driver gene score calculation
(see Additional file 1: Table 1 and Table S9). The
CDH1 gene was found to be abundantly mutated in DGC
Table 1 Top candidate driver genes in 14 diffuse-type gastric cancers
Gene Samples, n nsSNVs, n SNVs in splice site, n Indels, n P-value Driver gene score
PIK3CA 5 5 0 0 3.63 × 10−12 9.83
CDH1 5 4 1 1 4.64 × 10−10 8.02
SNRPN 2 2 0 0 1.86 × 10−07 5.60
TP53 2 2 0 0 4.88 × 10−07 5.36
CMKLR1 2 2 0 0 5.33 × 10−07 5.36
CYP2A7 2 2 0 0 1.53 × 10−06 4.99
GUCY1B3 2 2 0 0 1.97 × 10−06 4.99
PAPOLB 2 2 0 0 2.15 × 10−06 4.99
MYH9 3 3 0 0 2.27 × 10−06 4.99
FAM71B 1 2 0 0 2.51 × 10−06 4.99
C10orf90 2 2 0 0 3.76 × 10−06 4.86
AKAP8 2 2 0 0 4.59 × 10−06 4.81
ZC3H12B 2 2 0 0 5.87 × 10−06 4.74
SFTA3 1 1 0 0 6.86 × 10−06 4.70
SENP7 2 2 0 0 7.65 × 10−06 4.68
TMPRSS6 2 2 0 0 8.38 × 10−06 4.67
PAGE2 1 1 0 0 9.94 × 10−06 4.62
For additional driver gene lists, see Additional file 1: Table S9.
Table 2 CDH1 alterations in 18 gastric cancers
Sample Type Alteration CDH1 region
D-01 T CNV Loss Exons 1 to 16
D-02 T SNV N256S Exon 6
CNV Loss Exons 1 to 16
D-03 T SNV Splice site Donor site of Intron 4
D-04 T CNV Loss Exons 1 to 16
D-05 T SNV D257N Exon 6
INS S829fs Exon 16
D-09 T SNV V252G Exon 6
SV Break point Intron 2
D-10 T CNV Loss Exons 1 to 16
D-11 T CNV Loss Exons 1 to 16
D-12 T SNV Q23* Exon 2
D-13 T CNV Loss Exons 1 to 16
SV Break point Introns 2 and 10
D-14 T SV Break point Introns 2, 5 and 9
I-01 T CNV Loss Exons 1 to 16
I-02 T CNV Loss Exons 1 to 16
I-03 T SNV D221G Exon 5
SV Break point Introns 10 and 13
I-04 T CNV Loss Exons 1 to 16
CNV, copy number variation; INS, small insertion; SNV, single nucleotide
variation; SV, structural variation.
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missense, one nonsense, one frameshift, and one splice
site mutations) that have not been reported previously,
whereas only one missense mutation was found in the
IGC samples (Table 2). All seven CDH1 somatic muta-
tions were verified by Sanger sequencing (see Additional
file 1: Table S10 and Table S11). In our DGC samples,
35.7% (5/14) had CDH1 somatic mutations, and it has
been reported that the frequencies of CDH1 somatic mu-
tations in sporadic DGCs can vary from 3% to greater
than 50% [19,37-40]. It was verified that in countries with
a high incidence of sporadic GC (such as Japan and
Korea), the frequency of germline mutations in familial
GCs is low compared with that in low-incidence countries
[41,42]. Therefore, we speculate that the overall GC inci-
dence is also related to the frequency of CDH1 somatic
mutations. Additionally, one germline mutation (T340A)
in CDH1 was found in both tumor and corresponding
blood genomes from two samples (D-14, DGC; M-01,
MSI-type). Although T340A is a causative mutation in
HDGC [43], these two patients did not have any familial
history such as GC or lobular breast cancer. Two previous
reports analyzing exome data of GC did not identify
CDH1 as a highly ranked gene (only one missense muta-
tion in an MSI IGC sample) [22,23]. This discrepancy may
be due to the small number of samples of DGC in those
studies (2 out of 22 and 3 out of 15 samples were DGCs,
respectively). In the present work, PIK3CA and TP53,
well-known cancer-associated genes, were the most
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Table 1 and Table S9 in Additional file 1. Mutations in
two known PIK3CA hotspots (E545K and H1047L)
were found in four DGC samples. Additionally, one
nsSNV mutation (Q546K) adjacent to the E545K muta-
tion was found in one DGC sample. In total, 5 out of 14
DGC samples (approximately 30%) harbored nsSNVs in
PIK3CA, which is an oncogene whose mutated form
exhibits increased kinase activity, causing cancer cell
proliferation [44]. We then compared the low fre-
quency (16–17%) of the nsSNVs in PIK3CA in reports
by others [22,23,44] (who mostly used IGC samples)
and the results of our combined analysis (31.5% for
DGC, 14.3% for IGC) (see Additional file 1: Table S9).
It appears that the relatively high mutation rates of
PIK3CA in DGC may reflect the specificity of muta-
tions in this gene to this type of cancer. Additionally,
three samples (two DGC and one IGC) contained both
nsSNV and a copy loss of TP53, indicating a homozy-
gous loss of function in TP53, as previously reported
[45]. An SNP in the PSCA gene (rs2976329) has been
reported to be associated with increased risk of DGC
in Japanese and Korean populations [21]. This SNP was
also enriched in the majority of DGC samples in our
study, (9 out of 14 patients), indicating that our analyzed
samples represent typical patients with DGC in East
Asia. Additionally, a nonsense mutation (R1446*) in
the ARID1A gene, was found in one DGC sample (D-08).
Although mutations in ARID1A are frequently detected in
MSI and in EBV-positive GCs [22,23], the D-08 sample
showed no EBV infection, and an MSI sample (M-01) did
not have any ARID1A gene mutations either. From varia-
tions in candidate driver genes, 88 nsSNVs, 4 small indels,
and 2 SNVs in a splice site were verified using conven-
tional Sanger sequencing. Seven of these mutations
could not be tested because of PCR failure, and of the
remaining 87 mutations, 96.6% were confirmed as true
somatic mutations (see Additional file 1: Table S10 and
Table S11).
The somatic variations were then mapped onto the
Kyoto Encyclopedia of Genes and Genomes (KEGG)
pathways database. This analysis revealed that the mutated
genes of DGCs were significantly associated with the cal-
cium signaling pathway (P = 7.00 × 10−5; see Additional file
1: Table S12 and Table S13). Low calcium intake may con-
tribute to GC development [46]. Calcium is essential for
the function of E-cadherin, and a loss of E-cadherin-
mediated adhesion is involved in the transition from a be-
nign lesion to invasive metastatic cancer [47]. Furthermore,
the somatic mutations were strongly associated with path-
ways related to small cell lung cancer (P = 1.00 × 10−6 in
DGC and P = 4.24 × 10−2 in IGC). In particular, genes in-
volved in focal adhesion pathways, such as ITGA, PIK3CA,
and PTEN, were frequently mutated.SV and CNV analysis
SVs were detected based on discordantly mapped read
pairs, and any SVs that were present in the patients’
germline genomes were excluded. On average, we found
552 somatic SVs per DGC sample pair (211 large inser-
tions, 264 large deletions, 27 inversions, 44 intrachromoso-
mal translocations, and 6 interchromosomal translocations).
We found 664 somatic SVs in each IGC sample pair (285
large insertions, 283 large deletions, 34 inversions, 38 intra-
chromosomal translocations, and 24 interchromosomal
translocations) (for details for each sample, see Additional
file 1: Table S14 and Figure S3). Additionally, we found
2,258 genes to be impaired, and 1,736 of these were
found only in the DGC samples (for data for each sam-
ple, see Additional file 1: Table S15; and see Additional
file 3). Three tumor suppressor genes FHIT, WWOX,
and MIPOL1, which were reported in a previous GC study
[30], had impairments due to the SVs (FHIT in 11 sam-
ples, WWOX in 5 samples, andMIPOL1 in 3 samples).
Fusion genes generated by a chromosomal rearrange-
ment were also analyzed, and 19 fusion gene candidates
were identified (see Additional file 1: Table S16), includ-
ing a novel fusion gene, TSC2-RNF216, found in one
sample (Figure 2a, b). TSC2 encoding the tuberin pro-
tein was previously suggested as a tumor suppressor
gene involved in the mammalian target of rapamycin
(mTOR) pathway [48,49]. In addition, RNF216, encoding
E3 ubiquitin-protein ligase, is involved in cytokine func-
tion by preventing the sustained activation of nuclear
factor (NF)-κB [50]. The Rap GTPase activating protein
(Rap-GAP) domain of the TSC2 protein, which is related
to the intrinsic GTPase activity of the Ras-related pro-
teins RAP1A and RAB5, was broken by this chromosomal
translocation (Figure 2c). In addition, the zinc finger do-
mains of the RNF216 protein were not expressed in the
fusion gene, because of a frameshift that caused premature
termination. Using reverse transcription polymerase chain
reaction (RT-PCR) followed by sequencing analysis, the
expression of this fusion gene in the patient’s tissue was
confirmed. After testing an additional set of 15 GC patient
tissues, we identified 2 patients expressing the fusion gene
(Figure 2d, e). This chromosomal translocation can lead to
altered cellular behavior both by disrupting the normal
functioning of the gene and causing expression of the fu-
sion gene product, which may compete against the normal
gene. The fusion gene can competitively interfere with
tumor suppressor pathways and activate NF-κB-mediated
cytokine signaling.
In DGCs, chromosomes 16, 17, 19, 20, 21, and 22 con-
tained an increased amount of block deletions, while
chromosomes 3, 7, 8, and 13 showed notably increased
duplications (Figure 1). Many tumor suppressor genes,
such as CDH1, PLA2G2A, RUNX3, SMAD2, and TP53,
are located in extensively deleted chromosomal regions.
Figure 2 TSC2-RNF216 fusion gene breakage. (a) Exon structure of the TSC2-RNF216 fusion gene. The numbers in the boxes are the exon
numbers of each gene. Red lines indicate the fusion points. (b) Protein domain structure of the TSC2-RNF216 fusion protein. The Rap-GAP domain
of TSC2 was broken, and RNF216 had a frameshift mutation causing premature termination by the interchromosomal rearrangement. (c) Structure
of the TSC2 Rap-GAP domain. The red region is the remaining Rap-GAP domain region, and the gray region is the Rap-GAP domain that is deleted
in the TSC2-RNF216 fusion gene. (d) RNA sequence of the TSC2-RNF216 fusion gene. Position 136 is shown as N. Either an A or G base produces
a termination codon (TAA or TAG). (e) Verification of the TSC2-RNF216 fusion transcript in RNA (cDNA) by means of PCR amplification
and electrophoresis.
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tion) and copy number loss of CDH1 were generally mu-
tually exclusive: four out of five DGC samples with
somatic mutation did not have gene copy number losses,
and eight out of nine DGC samples with a CDH1 gene
copy number loss did not have any somatic mutations inCDH1. Only one sample (1/18, 5.6%) had both alter-
ations (mutation and copy number loss) concomitantly,
and this observation coincides with previous studies
reporting that concomitant alterations in CDH1 are rare
[19,40,51,52]. When we considered SVs in CDH1 together,
we found that other three samples had a mutation/copy
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numbers of the oncogene MYC were increased in five
DGC samples (see Additional file 4), and copy numbers of
MET were increased in three DGC samples [53]. The on-
cogenes MOS and ZHX2 also showed a copy number gain
in five and four DGC samples, respectively. More than half
of the samples (10 out of 18) showed a copy number reduc-
tion of ARID1A, which is a driver gene for ovarian clear cell
carcinoma, and a chromatin remodeler in GC [22,54,55]. It
is known that the majority of GCs with ARID1A mutations
show lower protein expression compared with GCs without
an ARID1A mutation [22]. If the dosage effect is important
in these cancer tissues, copy number reduction of ARID1A
could be a possible cancer-associated factor.Figure 3 The duplication region of the MDM2 gene on chromosome 1
two chromosomes. (b) Thin black spikes were read at mapping depth of 2
approximately 30 times sequencing depth. (c) Gene positions and names arou
transcript levels in tumor and adjacent normal tissue paired samples and norma
in samples D-01 and D-02 (containing amplified MDM2 regions), D-04, D-05, D-
lines (HDF, HMEC, and Hs 738.St/Int). Error bars were calculated from two separA large region of chromosome 12 was amplified in
three DGC genomes; of these three genomes, samples
D-01 T and D-02 T showed distinctively high amplifica-
tion (Figure 3a). The duplication patterns were slightly
different: D-01 T had a tandem duplication of 3 Mbp,
whereas D-02 T had an inverted duplication of 1 Mbp
(Figure 3b, c). Part of this duplicated region encodes the
murine double minute (MDM2) gene. It was reported
that in a small dataset, the MDM2 gene was frequently
amplified [56], and that this gene is associated with sev-
eral cancers [57]. MDM2 overexpression caused by the
gene amplification was experimentally confirmed using
quantitative RT-PCR with the tumor and adjacent normal
tissue paired samples used for NGS analyses, and normal2 in samples D-01 T and D-02 T. (a) Mapping depth plots of the
000-base width. The y-axis shows relative depth. Each unit represents
nd the amplified regions. The black bands show gene locations. (d) MDM2
l cell lines. Quantitative RT-PCR was used to measure MDM2 mRNA levels
10, I-03, and I-04 (without amplified MDM2 regions), and three normal cell
ated experiments of triplicate reactions.
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MDM2 overexpression positively correlated with the copy
number analysis data. Although previously reported
array CGH data [32] had relatively low resolution for
CNV detection, we used those data to search for a bias
in alterations of gene copy number in each histopatho-
logical type. A copy number gain of genes encoding
calcium channel proteins (CACNG6, CACNG7, and
CACNG8, P = 4.24 × 10−2) was significantly more com-
mon in DGC samples (see Additional file 1: Table S17).
All integrated alteration information is shown in
Additional files (see Additional file 1: Table S18 and
Table S19; see Additional file 5).Figure 4 Structure of the CDH1 protein and EC1-2 junction. (a) The fu
Sites of non-synonymous mutations and deletions are shown with red line
extracellular cadherin (EC) domains. (c) CDH1 has five EC domains (EC1–EC
EC3-4, and EC4-5). The green spheres represent Ca2+ ions. The red and blu
reported mutations found in hereditary diffuse-type gastric cancer, respective
D221G mutation, oxygen atoms of the aspartic acid side chain, which normal
with a glycine. In the case of the D257N mutation, the two oxygen atoms of
when aspartic acid is replaced with asparagine. In the N256S mutation, the ox
between the oxygen atom and the Ca2+ ion is increased from 2.52 Å to
System (v0.99rc6; Schrödinger LLC).3D structural analysis of mutated CDH1
To understand how the detected mutations affect pro-
tein structure/function and activation of downstream
biological pathways influencing carcinogenesis, we ana-
lyzed three-dimensional (3D) structures of the mutant
E-cadherin protein found in one IGC and five DGC
samples (see Additional file 2). The CDH1 gene encodes
a calcium-dependent cell adhesion glycoprotein and has
five extracellular cadherin domains (EC1-EC5) (Figure 4a).
It is known that the interaction between cadherin and cal-
cium is required for dimerization, structural rigidity, and
protection from proteolytic degradation [58]. Mutations in
the EC1-2 and EC2-3 junctions are known to causell-length E-cadherin protein has 882 amino acid residues in 7 domains.
s. (b) Red lines and triangles indicate non-synonymous mutations in
5, which form a β-barrel structure) and four EC junctions (EC1-2, EC2-3,
e spheres represent somatic mutations found in this study and previously
ly. (d, e) CDH1 mutation sites in the EC1-2 junction. In the case of the
ly interact with Ca2+, are absent when the aspartic acid residue is replaced
the Asp side chains become one oxygen atom and one nitrogen atom
ygen atom of the asparagine side chain is preserved, but the distance
3.73 Å. All structures were drawn by using PyMOL Molecular Graphics
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sion [59]. Structural analysis was carried out on four
nsSNVs (D221G, V252G, N256S, and D257N), excluding
a nonsense SNV (Q23*), a frameshift insertion (S829fs),
and a splice site (chr16:68842472) mutation. All four
nsSNVs were located in the junction between EC1 and
EC2 (EC1-2 junction) (Figure 4b, c), and three nsSNVs
(D221G, N256S, and D257N) were in the protein region
that directly interacts with a calcium ion (Figure 4d, e).
This situation could result in anomalous interactions be-
tween the cadherin domains. It is reported that A298T,
D231K, and D231A mutations, which have a similar struc-
tural position at the EC1-2 junction to the somatic muta-
tions found in this study, showed a loss of cell adhesion
function [60,61]. Another nsSNV mutation, V252G, is
located in the β-sheet structure of cadherin, and its
side chain is oriented towards the interior. Because β-
barrel structures generally contain alternating polar and
hydrophobic amino acids, with the hydrophobic residues
oriented toward the interior of the barrel to form a hydro-
phobic core, and the polar residues oriented toward the
outside of the barrel on the solvent-exposed surface, the
formation of the hydrophobic core may be hindered by
the V252G mutation (Figure 4e). A previous exome study
reported two CDH1 mutations, P127fs (frameshift muta-
tion in a DGC) and V694I (in an MSI IGC) [22].
Dimerization of two cadherin molecules in either a cis or
trans configuration occurred at the junction between
EC1-2 and EC1-2 [62], whereas mutations at the EC3-4
and EC4-5 junctions did not significantly affect cell adhe-
sion [59]. Val694 is located in a loop region between the
EC5 β-barrel and a transmembrane region distant from the
EC1-2 and EC2-3 junctions. Accordingly, the V694I muta-
tion may not be disruptive to E-cadherin protein function.
Moreover, Val and Ile have a similar hydrophobic side chain
and are similar in size.
Additionally, we structurally analyzed previously re-
ported 19 missense mutations in CDH1 (see Additional
file 1; Table S20), which were found in hereditary DGC
[60,63-65]. We found that the in vitro functional changes
by the missense mutations corresponded exactly to the ef-
fects on calcium interaction and structural integrity as de-
scribed above. The somatic mutations that we found were
concentrated in the EC1-2 junction region, whereas the
19 germline mutations were scattered throughout the
E-cadherin protein (Figure 4c). This finding coincides
with previous results that germline CDH1 mutations
are not restricted to specific E-cadherin domains, but
are distributed throughout all protein functional do-
mains [66]. In this study, we identified four somatic
missense mutations in exons 5 and 6, and it is known
that somatic CDH1 mutations found in sporadic DGCs
cluster in exons 7 to 10 [66,67]. Exons 5 and 6 encode
the structural components of EC1, EC2, and EC1-2junction, as in the case of exons 7 and 8. Taken to-
gether, these results suggest that CDH1 somatic muta-
tions in the EC1-2 junction that disrupt cell adhesion
function are prevalent in DGCs, and thus that dysfunc-
tion of the EC1-2 junction is specific to DGC.
Conclusions
WGS and WES were used here to identify somatic varia-
tions that are characteristic of DGC. The samples con-
tained both DGC and normal cells, such that the sample
purity range was as low as 20% according to our genomic
profile analyses. Our approach (WGS combined with ex-
ome data with sequencing depth of greater than 120
times) resulted in accurate detection of SNVs and indels
in genic regions. The efficacy of this approach is evident
in the verification data, which showed a positive rate of
96.6% for somatic SNVs and indels. This combination ap-
proach also has the benefit of detecting SVs and large-
scale abnormalities, whereas WES alone can identify only
somatic variations such as SNVs and indels in exonic re-
gions. This strategy may facilitate analysis of heterogeneous
cancer cells, an important issue in cancer genomics [68].
To the best of our knowledge, this is the first extensive
genomic analysis of DGC. We identified somatic SNVs
and indels in the DGC samples, compared with the IGC
samples. We also found SVs and a novel fusion gene in
GC samples, although their functional effects need to be
validated in further studies. CDH1 mutations are known
to be prevalent in several types of cancers: gastric, colo-
rectal, breast, thyroid, and ovarian. E-cadherin dysfunc-
tion is the most well-established defect in GC development,
and our data support its importance in DGC. The DGC
samples showed a high frequency of somatic mutations in
CDH1, and protein structural analysis suggested that the
mutations influence the interaction between E-cadherin and
calcium, and the stability of β-barrel structures of cadherin.
These results indicate that CDH1 and the calcium signaling
pathway are associated with the pathogenesis of DGC. Our
data from GC genomes should improve the understanding
of the mechanism via which protein structural perturbations
can cause pathological changes and possibly lead to cancer
development. This knowledge may help to diagnose and
treat GCs in a more individualized manner, taking into ac-
count the different subtypes.
Materials and methods
Patients and specimen collection
This study was performed in accordance with the Declar-
ation of Helsinki and was approved by the local ethics com-
mittee of the National Cancer Center (IRB No. NCCNCS-
10-392). Signed informed consent was obtained from all
participants before enrolment.
GC specimens and peripheral blood samples were col-
lected from 18 patients (14 with DGC and 4 with IGC) who
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Center, South Korea, between 2005 and 2010 (see Additional
file 1: Table S1). Tumor and adjacent normal specimens
were examined by pathologists to remove the necrotic region
and the intervening tissue, in accordance with the World
Health Organization histopathological criteria. After patho-
logical examination, the samples were snap-frozen and
stored in liquid nitrogen until genomic DNA extraction.
Nucleic acid preparation
The frozen tumor samples were macro-dissected and
lightly stained with hematoxylin to identify regions con-
sisting of 80% or more cancer cells. Genomic DNA was
extracted with the MagAttract DNA Blood Midi Kit
(Qiagen Inc, Valencia, CA, USA), in accordance with the
manufacturer’s protocol. DNA quality was assessed using
a Nanodrop spectrometer (Nanodrop Technologies,
Wilmington, DE, USA). Control DNA from matched
peripheral blood samples was processed in the same
manner. The same frozen tumor samples were used
for total RNA extraction using a Qiagen RNeasy Mini
Kit (Qiagen). Quality of total RNA was assessed with
Lab-on-a-Chip on an Agilent 2100 Bioanalyzer (Agli-
ent Technologies, Santa Clara, CA, USA). The total
RNA (1 μg) was used in a reverse transcription reaction
with poly (dT) primers using the SuperScriptTMIII First-
Strand Synthesis system (Invitrogen/Life Technologies,
Grand Island, NY, USA), in accordance with the manufac-
turer’s instructions. DNA and RNA of adjacent normal
tissues were obtained using same methods as tumor
samples.
Whole genome sequencing
Genomic DNA was sheared using Covaris S series (Covaris,
MS, USA). The sheared DNA was end-repaired, A-tailed,
and ligated to pair-end adapters, in accordance with the
manufacturer’s protocol (Pair End Library Preparation Kit,
Illumina, San Diego, CA, USA). Adapter-ligated fragments
were purified and dissolved in 30 μl of elution buffer, and
1 μl of the mixture was used as a template for 12 cycles of
PCR amplification. The PCR product was gel-purified using
the QIAquick Gel Extraction Kit (Qiagen). Library quality
and concentration were determined using an Agilent 2100
BioAnalyzer (Agilent). Libraries were quantified using a
SYBR green qPCR protocol on a LightCycler 480 (Roche,
Indianapolis, IN, USA), in accordance with Illumina’s li-
brary quantification protocol. Based on the qPCR quantifi-
cation, libraries were normalized to 2 nM, and then
denatured using 0.1 N NaOH. Cluster amplification of de-
natured templates was performed in flow cells, in accord-
ance with the manufacturer’s protocol (Illumina). Flow cells
were paired-end sequenced on an Illumina HiSeq 2000
using HiSeq Sequencing kits. A base-calling pipeline
(Sequencing Control Software (SCS), Illumina) wasused to process the raw fluorescent images and the
called sequences.
Exome sequencing
WES was performed using SureSelect Human All Exon
44 Mb (Agilent), following the manufacturer’s standard
protocol. Briefly, a paired-end DNA sequencing library
was prepared through genomic DNA shearing, end-
repair, A-tailing, PE adaptor ligation, and amplification.
After hybridization of the library with bait sequences for
24 hours, the captured library was purified and amplified
with an index barcode tag, and the library quality and
quantity were determined. Sequencing of the exome li-
brary was carried out using the 100 bp paired-end mode
of the HiSeq SBS kit, in accordance with the manufac-
turer’s manual.
Read alignment and variation detection
Paired-end sequence reads were aligned to the hg19 human
reference genome (NCBI build 37) with the Burrows-
Wheeler Aligner (BWA) [69] (v0.5.9). Two mismatches
were permitted in a 45 bp seed sequence. The rmdup com-
mand of SAMtools was used to remove PCR duplicates of
sequence reads, which can be generated during the library
construction process [70]. Aligned reads were realigned at
putative indel positions with the Genome Analysis Toolkit
(GATK) [71] IndelRealigner algorithm to enhance mapping
quality. Base quality scores were recalibrated using the
TableRecalibration algorithm of GATK.
SNP and small insertion/deletion analysis and somatic
mutation filtering
Putative SNVs were called and filtered using the Unified-
Genotyper and VariantFiltration commands in GATK.
The options used for SNP calling were a read mapping
depth of 5 to 200 times with a consensus quality of 20,
and a prior likelihood for heterozygosity value of 0.001.
To obtain small indels, the UnifiedGenotyper DINDEL
mode of GATK was used with default values, including a
window size of 300 bp. To identify somatic mutations in
cancer genomes, mutations from cancer genomes were
filtered using the mutations from blood genomes. The
remaining mutations were filtered again using the map-
ping status of the blood genomes. At each remaining
tumor mutation position, if the minimum mapping
depth was at least 3 and the mutation ratio of the blood
genome was at least 0.2, the tumor SNV was discarded. To
remove false-positive reads caused by genomic duplications,
the somatic mutations were called from uniquely mapped
reads. Additionally, mutations located in duplicated se-
quences (≥90% identity) were filtered out if the mutations
were not detected by both WGS and WES. The indels were
called from reads aligned using the Smith-Waterman algo-
rithm [72]. Two additional databases, dbSNP 131, and an
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found in 20 healthy Koreans, were used to filter out add-
itional SNVs. All somatic mutations altering amino acid se-
quences were checked by expert laboratory personnel using
the tview command of SAMtools. The same method was
applied to call SNVs and small indels from the previously re-
ported exome data, except for the step filtering mutations
located in duplicate sequences.
Mutation rate calculation
For the mutation rate calculation, the number of muta-
tions was compared with the total number of bases in
sufficiently covered coding DNA sequence (CDS) re-
gions. The mutations consisted of SNVs and small
indels. The sufficiently covered CDS region was defined
where its read mapping depth was at least five reads.
Sanger sequencing
A total of 94 nsSNVs, indels, and SNVs in splice sites
were verified by conventional Sanger sequencing using
dye-terminator chemistry and analyzed with an auto-
matic sequencer ABI 3730 (Applied Biosystems). The
target regions were amplified by PCR followed by direct
sequencing, or cloned into TA vectors. At least 20 TA
vector clones were sequenced, because mutations in low
purity samples are difficult to detect by Sanger sequen-
cing. Details of the PCR and sequencing primers are
given (see Additional file 1: Table S11).
Annotation of variations
Predicted SNVs were compared with NCBI dbSNP (ver-
sion 131) to annotate known SNP information. Each SNV
was mapped on the University of California Santa Cruz
(UCSC) gene table by genomic features such as coding re-
gion, untranslated region, and intron. Non-synonymous
SNV information was extracted by comparing UCSC ref-
erence gene information. The KEGG pathway [73] was
used to analyze altered protein sets. Information on
cancer-related mutations was obtained from COSMIC
(Catalogue of Somatic Mutations In Cancer) [74].
Driver gene prediction
Driver gene scores were calculated using SNVs as de-
scribed in a previous report [22], with an efficiently cov-
ered region with a normal sample mapping depth of 4
times or greater and a cancer sample mapping depth of
3 times or greater. In brief, the driver gene score was
calculated by comparing the observed number of nsSNVs
with the expected number. The expected number of nsSNVs
was calculated from the background non-synonymous to
synonymous SNV ratio, and the number of observed syn-
onymous SNVs. The P-value for a driver gene score was cal-
culated from the numbers of expected and observednsSNVs, assuming that the numbers of nsSNVs had a Pois-
son distribution.
Purity calculation
The purity of the cancer samples was determined by cal-
culating the mapping depths ratio of the diploid and the
haploid regions of the samples. Cancer samples usually
have a mix of diploid and haploid regions, which are
generated by heterozygous deletions. The first step is to
calculate the ratio of the mapping depths from cancer
and normal genomes by scanning the genomes with a
window size of 50 kb. If a sample does not contain any
tumor cells, there will always be only one peak in a
histogram that shows the mapping depth ratio. If there
are tumor cells, there will be two or more peaks (see
Additional file 1: Figure S1). Secondly, the purity is cal-
culated by the ratio distance(s) between the peaks using
the equation shown below.
Purity Pð Þ ¼ 2 R2n‐R1nð Þ
R2n
ð1Þ
R2n is the ratio of the diploid (2 N) region, and R1n is
the ratio of the haploid (1 N) region. When the purity
was lower than about 0.5, the peaks were not distinct.
To overcome this ambiguity, somatic deletion regions
detected by BreakDancer were used as the 1 N depth re-
gions [75]. The false-positive somatic deletion regions
were filtered out using the deletion regions detected in
the blood genomes. When the average depth ratio of the
somatic deletion region was greater than that of the
depth of the 2 N region, the deletion was regarded as a
false positive.
Identification of copy number variation regions
CNVs based on the differences in sequencing depths be-
tween normal and cancerous samples were detected
using BIC-seq [76] v1.1.2 with λ = 100 and bin_size =
1000 bp. Regions with a log2 ratio smaller than −0.2 or
larger than 0.2 were defined as deleted or duplicated re-
gions, respectively. The CNV candidates were mapped
to COSMIC [74] data to find cancer-associated genes.
For previously reported array CGH data [32], +0.152173
and −0.135797 were applied as thresholds for gain and
loss, respectively. Genes having its corresponding clones
were used for CNV analysis.
Identification of structural variants and gene fusions
SVs were scanned using BreakDancer [75] with score ≥80.
A somatic SV was defined as an SV not found in blood
samples. We obtained structural variation signals (SVSs),
which are clusters composed of more than three uniquely
and discordantly mapped read pairs from all SV regions.
We used SVSs found only in tumor tissue samples for
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the breakpoints of the two SVSs were 400 bp or closer to
each other. SVSs located in intergenic and intron region
were excluded. A gene was determined to have a breakage
event when an SVS breakpoint occurred within the
gene. Gene fusion was defined as a connection of two
genes by a SVS. The final gene fusion candidates were
selected when the number of supporting read pairs
was above 10, and the only interchromosomal gene fu-
sions were chosen.
Structure prediction of CDH1
The mutated structure of CDH1 (E-cadherin) was pre-
dicted by homology modeling using mouse E-cadherin
protein (PDBID:3Q2V) [77] as a template with MODEL-
LER [78] v9.10.
Genome-wide SNP analysis
SNP genotyping was performed using an Axiom geno-
typing solution with an Axiom Genome-Wide ASI 1
Array Plate and a reagent kit, in accordance with the
manufacturer’s protocol (Affymetrix). Briefly, total gen-
omic DNA (200 ng) was treated with 20 μl of denatur-
ation buffer and 40 μl of neutralization buffer, followed
by amplification for 23 hours using 320 μl of Axiom
amplification mix. Amplified DNA was randomly digested
into 25 to125 bp fragments with 57 μl of Axiom fragmen-
tation mix at 37°C for 30 minutes, followed by DNA pre-
cipitation for DNA purification and recovery. DNA pellets
were dried and resuspended in 80 μl of hybridization mas-
ter mix, and 3 μl of suspended sample was used for
sample qualification. A hybridization-ready sample was
denaturated by PCR at 95°C for 20 minutes and 48°C
for 3 minutes. The denatured DNA was transferred to
a hybridization tray, and loaded onto a GeneTitan MC
with an Axiom ASI array plate (Affytmerix). Hybridization
continued on the GeneTitan for 24 hours, after which
ligation, staining, and stabilization reagent trays were se-
quentially loaded onto the instrument. GeneTitan was
controlled by an Affymetrix GeneChip Command Console
GeneTitan Control (Affymetrix). The chip image was
scanned with the GeneTitan, and the resulting data, a
Image data (DAT) file, was automatically converted to a
Cell Intensity data (CEL) file. The CEL intensity file was
normalized, and genotype calling was performed using
Genotyping Console 4.1 with Axiom GT1 algorithms, in
accordance with the manufacturer’s manual. The cut-off
value for data quality control was a DISHQC of 0.82 or
greater for hybridization, and a call rate of 97% or greater.
MDM2 gene expression analysis by quantitative real-time
PCR
MDM2 mRNA expression was analyzed using a quanti-
tative real-time PCR system, and the MDM2 geneexpression was normalized to GAPDH. Primer se-
quences for MDM2 and GAPDH were as follows.
MDM2-RT forward sequence was 5′-GGCCTGC
TTTACATGTGCAA-3′, MDM2-RT reverse sequence
was 5′-GCACAATCATTTGAATTGGTTGTC-3′, GA
PDH forward sequence was 5′-TGCACCACCAACTG
CTTA-3′, and GAPDH reverse sequence was 5′- GG
ATGCAGGGATGATGTTC-3′. Quantitative real-time
PCR was performed with SYBR Green I PCR Master
Mix (Qiagen) on a LightCycler 480 Real-Time PCR
System (Roche). The experiments were performed in tripli-
cate, and the PCR reaction was performed as follows: 5 mi-
nutes at 95°C for initial denaturation, then 45 cycles at
95°C for 10 seconds, 58°C for 10 seconds, and 72°C for
10 seconds, followed by melting curve analysis at 95°C
for 5 seconds, 65°C for 1 minute, and cooling for
30 seconds at 40°C. For each reaction, 5 ng of cDNA,
500 nM primer (final concentration) and 5 μl of 2X
SYBR Green I PCR Master Mix was used in a 10 μl reac-
tion volume.Fusion gene analysis
Genomic rearrangement of the fusion gene was verified
by PCR using a forward primer located in TSC2 (5′-CT
CAGGTTCCGAGCCTAACAG-3′) and a reverse primer
in RNF216 (5′-GCAAACATAGTGAGACCCCATCT-3′).
The PCR reaction was performed as follows: 15 minutes
at 94°C for initial denaturation, then 40 cycles at 94°C
for 30 seconds, 60°C for 30 seconds, and 72°C for 1 mi-
nute, with 5 minutes at 72°C for post-extension. For
each reaction, 30 ng/μl gDNA, 100 nM primer, and 0.5
U of Taq polymerase (Qiagen) were used in a 20 μl re-
action. The expression of a fusion gene in one patient
sample was analyzed by RT-PCR using a forward
primer located in TSC2 (5′-GAGCATGGCTCCTA
CAGGTACAC-3′) and a reverse primer in RNF216
(5′-CTCTTCACAGGTGAGGCCATTAT-3′). The RT-
PCR reaction was performed as follows: 5 minutes at
94°C for initial denaturation, then 40 cycles at 94°C for
30 seconds, 60°C for 30 seconds, and 72°C for 1 mi-
nute, with 5 minutes at 72°C for post-extension. For
each reaction, 10 ng cDNA, 200 nM primer, and 0.5 U
of Taq polymerase (Solgent, Korea) were used in each
20 μl reaction. The RT-PCR products were analyzed
by Sanger sequencing using an automatic sequencer
(ABI3700; Applied Biosystems) to verify their fusion at
the sequence level.Data access
The data from this study have been submitted to NCBI
Sequence Read Archive (SRA) [79] under accession
number SRA057772 (WGS) and SRA057973 (WES).
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